Cabozantinib (XL-184) is another multi-kinase inhibitor that targets c-Met, VEGFR1, VEGFR2, VEGFR3, RET, TIE2, FLT-3 and KIT, so should block multiple pro-cancer signaling pathways [49]. The gene discussed is MET; the disease is cancer.